Showing papers by "Robert H. Bartlett published in 1994"

Photobioreactors and closed ecological life support systems and artifificial lungs containing the same

Abstract: A photobioreactor system for efficient oxygen production for a closed ecological life support system (CELSS) is disclosed. Special features of this system include, e.g., the optical transmission system, uniform light distribution, continuous cycling of cells, gravity independent gas-exchange, and an ultrafiltration unit. The fiber optic based optical transmission system illuminates the reactor internally and includes a light source which is external to the reactor, preventing heat generation problems. Uniform light distribution is achieved throughout the reactor without interfering with the turbulent regime inside. The ultrafiltration unit exchanges spent with fresh media and its use results in very high cell densities, up to 10 9 cells/ml for Chlorella vulgaris. The prototype photobioreactor system may be operated in a batch and continuous mode for prolonged periods of time. The photobioreactor may be used to convert CO 2 to oxygen in an artificial lung.

Extracorporeal life support for neonatal respiratory failure. A 20-year experience.

Abstract: Objective The authors reviewed their experience with extracorporeal life support (ECLS) in neonatal respiratory failure; they define changes in patient population, technique, and outcomes. Summary background data Extracorporeal life support has progressed from laboratory research to initial clinical trials in 1972. Following a decade of clinical research, ECLS is now standard treatment for neonatal respiratory failure refractory to conventional pulmonary support techniques. Our group has the longest and largest experience with this technique. Methods Between 1973 and 1993, 460 neonates with severe respiratory failure were treated using ECLS. The records of all patients were reviewed. Results Overall survival was 87%. Primary diagnoses were meconium aspiration syndrome (MAS; 169 cases [96% survival]), respiratory distress syndrome/hyaline membrane disease (91 cases [88% survival]), persistent pulmonary hypertension of the newborn (37 cases [92%]), pneumonia/sepsis (75 cases [84% survival]), congenital diaphragmatic hernia (CDH; 67 cases [67% survival]), and other diagnoses (21 cases [71% survival]). Common mechanical complications included clots in the circuit (136; 85% survival); air in the circuit (67; 82% survival); cannula problems (65; 83% survival) and oxygenator failure (34; 65% survival). Patient-related complications included intracranial infarct or bleed (54 cases; 61% survival), major bleeding (48 cases; 81% survival), seizures (88 cases; 76% survival), metabolic abnormalities (158 cases; 71% survival) and infection (21 cases; 48% survival). Since 1989, treatment groups have been expanded to include premature infants (13 cases; 62% survival), infants with grade I intracranial hemorrhage (28 cases; 54% survival) and "non-honeymoon" CDH patients (15 cases; 27% survival). Since 1990, single-catheter venovenous access has been used in 131 patients (97% survival) and currently is the preferred mode of access. Follow-up ranges from 1 to 19 years; 80% of patients are growing and developing normally. Conclusions Extracorporeal life support has become standard treatment for severe neonatal respiratory failure in our center (460 cases; 87% survival), and worldwide (8913 cases; 81% survival). The availability of ECLS makes the evaluation of other innovative methods of treatment, such as late elective repair of diaphragmatic hernia and new pulmonary vasodilators, possible. The application of ECLS is now being extended to premature and low-birth weight infants as well as older children and adults.

Extracorporeal life support for respiratory failure after multiple trauma.

Abstract: Respiratory failure may complicate multiple trauma and can add significant morbidity, mortality, and cost to the care of such patients. We used extracorporeal life support (ECLS) to treat 24 patients with multiple trauma who, after their injury, developed respiratory failure refractory to conventional ventilatory management. Injuries in these patients were the result of motor vehicle crashes (16 patients), pedestrian versus car collisions (3 patients), gunshots (2 patients), stabs (1 patient), and a recreational vehicle crash (1 patient). Patients were placed on venovenous or venoarterial ECLS, using continuous systemic anticoagulation with heparin, and percutaneous cannulation where possible. Average time on ECLS was 287 +/- 43 hours (12 +/- 1.8 days). The major complication was bleeding, which occurred in 75% of patients. Fifteen patients survived to be discharged from the hospital (63% survival). Early intervention (mechanical ventilation < or = 5 days prior to ECLS) was associated with good outcome. Despite risks of anticoagulation in patients with multiple injuries, ECLS can be life-saving in cases of respiratory failure refractory to conventional mechanical ventilation.

Efficacy of extracorporeal life support in the setting of adult cardiorespiratory failure.

Abstract: The efficacy of extracorporeal life support (ECLS, ECMO) in the management of severe adult cardiorespiratory failure remains controversial. The purpose of this review is to evaluate the authors' institutional experience with ECLS in adult patients. Between 1988 and 1993, 65 moribund patients with respiratory (n = 51) and cardiac (n = 14) failure were supported with ECLS. Criteria for initiation of ECLS were: 90% chance of mortality despite maximal conventional respiratory management, good potential for recovery, and age younger than 60 years. Venovenous bypass was used in 40 and venoarterial in 25 patients. Respiratory management included low rate, low pressure ventilation with an inspired oxygen fraction < or = 0.5 and tracheostomy tube placement. Continuous systemic heparinization was used, maintaining whole blood activated clotting time (ACT) between 180 and 200 sec. Survival data are summarized as follows: pneumonia (n = 25) 56%, adult respiratory distress syndrome (n = 24) 58%, airway support (n = 2) 100%, and cardiac support (n = 14) 29%. The most common complication was bleeding (68%), which was managed in most patients by reduction of anticoagulation or local measures such as packing. Data from survivors and nonsurvivors of ECLS in patients with respiratory failure were compared in an attempt to define prognostic indicators of improved survival. The only prognostic indicator of survival that could be identified was the period of time on the ventilator before the initiation of ECLS (survivors = 3.0 +/- 2.4 days, nonsurvivors = 6.1 +/9- 4.0 days, P < 0.005). It is concluded that ECLS can be a life saving modality for the management of severe adult cardiorespiratory failure. Earlier institution of ECLS in the course of cardiopulmonary failure may improve outcome.

The development of an implantable artificial lung

Abstract: This report describes the development of an implantable gas exchange device. The device is composed of hollow fiber elements wound around a central open core enclosed in a compliant outer casing, offering very low resistance to blood while providing adequate gas exchange. The purpose of this study was to determine if this device design can completely support the gas exchange requirements of a large animal when the device is placed in series with the main pulmonary artery (PA). Six 40-80 kg adult sheep were used. The device was placed with vascular grafts anastomosed end to side on the proximal and distal main PA. The study began with the entire right ventricular blood flow being diverted through the device by occlusion of a snare around the PA between the vascular grafts. Total gas exchange then was provided by the device and the endotracheal tube was clamped. Results showed that this pumpless potentially implantable device is capable of completely supporting the gas exchange requirements of the experimental animals for up to 8 hours in the acute setting without significant change in cardiac index (CI) and oxygen consumption (VO2) compared with baseline. CI = 55.0 +/- 17.0 cc/min/kg versus 45.0 +/- 17.3 cc/min/kg. VO2 = 1.90 +/- 0.96 cc O2/min/kg versus 2.08 +/- 0.54 cc O2/min/kg.

Alveolar-arterial oxygen gradients before extracorporeal life support for severe pediatric respiratory failure: Improved outcome for extracorporeal life support-managed patients?

Abstract: Objective: Recent reports have described the usefulness of the alveolar-arterial oxygen tension difference (P[A-a]o 2 ) in predicting mortality in children with acute respiratory failure managed with mechanical ventilation. We reviewed our experience with extracorporeal life support for acute pediatric respiratorg failure and specifically examined P(A-a)o 2 measurements during the 24 hrs before extracorporeal life support to determine if defined cutoffs established with conventional mechanical ventilation were applicable to extracorporeal life-support survival. Design: Strospective, case-series chart review. Setting: A university tertiary medical center

An intrapleural lung prosthesis: rationale, design, and testing.

Abstract: Extracorporeal life support (ECLS or ECMO) is standard treatment for severe respiratory failure but poses many contraindications to future lung transplantation. The solution to this dilemma is the implantable gas exchange device (IGED) or artificial lung. Preliminary efforts to create such an artificial lung have been made since 1970 and include designs involving single devices, intravascular devices (i.e., IVOX), and combination heart-lung devices. Stringent requirements govern the design of such a device, the most important of which are high gas exchange efficiency, low resistance to blood flow, and size. This paper describes such a device. It incorporates large diameter inflow and outflow ports in close proximity and a low resistance wound hollow fiber core encapsulated in a compliant outer shell which conserves the work of the right ventricle. In a large animal model (adult sheep) this device was connected in line with the main pulmonary artery in series with the native lungs. This configuration has the advantages of using the lungs as an embolic filter, perfusing the lungs with fully oxygenated blood, and maintaining the integrity of the anatomy necessary for transplant. Laboratory experiments have run > 8 h. Preliminary data show that the animals have remained hemodynamically stable while the devices have supported the animals completely by supplying 100% O2 saturation with PO2 values ranging from 250-350 mm Hg. Additionally, this model makes possible the study of respiratory failure without introducing other variables such as extracorporeal circuits or pumps. The other metabolic, endocrine, and reticuloendothelial functions of normal and injured lungs can now be studied more precisely by excluding these variables.(ABSTRACT TRUNCATED AT 250 WORDS)

Extracorporeal life support for severe pediatric respiratory failure: an updated experience 1991???1993

Abstract: OBJECTIVE The purpose of this study was to examine our recent experience with children who had acute respiratory failure managed with extracorporeal life support (ECLS) from 1991 to 1993, to determine whether a change in survival rate had occurred in comparison with our previous experience. DESIGN Historic and prospective cohort study. SETTING A tertiary pediatric referral center. PATIENTS All non-neonatal pediatric patients treated with ECLS for severe, life-threatening respiratory failure were examined. Overall, 25 patients have been managed with this life-support technique in the past 28 months. Eighty-four percent (21/25) were transferred to our medical center because of failure of conventional mechanical ventilation therapy. Descriptive data of the recent cohort were as follows (mean +/- SD): age 60 +/- 75 months, weight 23.6 +/- 24.8 kg, and male gender 44%. Duration of intubation before ECLS was 5.8 +/- 2.7 days. Arterial blood gas values and ventilator settings immediately before ECLS were as follows: fraction of inspired oxygen, 0.98 +/- 0.08; mean airway pressure, 21.6 +/- 6.2 cm H2O; peak inspiratory pressure, 45.5 +/- 9.6 cm H2O; positive end-expiratory pressure, 11.0 +/- 4.3 cm H2O; partial pressure of oxygen (arterial), 56 +/- 20 mm Hg (7.4 +/- 2.7 kilopascals); partial pressure of carbon dioxide (arterial), 46 +/- 17 mm Hg (6.1 +/- 2.3 kPa); and estimated alveolar-arterial oxygen tension difference, 572 +/- 81 mm Hg (76.3 +/- 10.8 kPa). Mean duration of ECLS was 373 +/- 259 hours. Of 25 recently treated patients, 22 (88%) survived their life-threatening respiratory illness to be discharged home; this represented a statistically improved survival rate in comparison with the 58% survival rate previously reported by us for similar patients (p < 0.05). Comparisons of arterial blood gas and mechanical ventilation-related variables measured 24 hours before and again immediately before bypass were similar in the two cohorts with the exception of higher mean partial pressure of carbon dioxide (arterial) 24 hours before bypass in the recent treatment group. For our entire experience, younger age groups had greater survival rates; 100% of infants less than 1 year of age survived. CONCLUSIONS Treatment with ECLS is an evolving pulmonary rescue therapy with an 88% survival rate in our recent experience. The survival rate has improved to levels that may not greatly improve in the near future, especially for patients less than 1 year of age. Better patient selection or improved management strategies or both may be responsible for the improved patient outcome.

Listeria monocytogenes and Severe Newborn Respiratory Failure Supported With Extracorporeal Membrane Oxygenation

Abstract: Objective: To determine the efficacy of extracorporeal membrane oxygenation (ECMO) in newborn infants with early-onset Listeria monocytogenes infection, necrotizing pneumonia, and severe respiratory failure. Design: Patient series. Setting: ECMO referral centers. Participants: The Extracorporeal Life Support Organization Registry database of patients supported with ECMO between 1975 and 1991. Intervention: ECMO. Measurements and Results: Nine neonates were identified who were supported with ECMO for severe respiratory failure associated with L monocytogenes infection. Microbiologic studies demonstrated L monocytogenes organisms in the blood of all infants, and pneumonia was diagnosed by roentgenogram and/or isolation of L monocytogenes organisms in tracheobronchial secretions. All infants experienced progressive respiratory deterioration by age 36 hours and were placed on venoarterial bypass by 96 hours, having met institution-based criteria predictive of 80% to 90% mortality. The duration of ECMO for patients with Listeria infection (median, 210 hours; range, 137 to 454 hours) was prolonged compared with the duration of ECMO for neonates in all other registry diagnostic categories (median, 114 hours; range, 1 to 744 hours; N=5146, P =.035). Six of the nine infants recovered completely. Conclusions: These data suggest that ECMO is efficacious in patients with severe respiratory failure secondary to Listeria sepsis. Prolonged time on bypass should be expected when Listeria sepsis is associated with severe necrotizing pneumonia. (Arch Pediatr Adolesc Med. 1994;148:513-517)

The management of acute respiratory failure.

Abstract: The mortality rate of severe respiratory failure in most centers remains 60% to 90% with conventional pulmonary support techniques. Recent advances in the physiologic management of patients with acute respiratory failure include optimizing systemic oxygen delivery as reflected by continuous mixed-venous saturation monitoring, avoidance of the damaging effects of high inflation pressures and volumes during mechanical ventilation, and the increasing application of extracorporeal life support techniques for refractory respiratory failure. The future promises the routine clinical application of novel support techniques including implantable intracorporeal gas exchange devices and perfluorocarbon liquid ventilation.